Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide+Decitabine+Anti-PD-1 vs BV+Anti-PD-1 in R/R cHL
NCT06393361Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, decitabine in classical Hodgkin lymphoma (cHL), sponsored by Chinese PLA General Hospital. Started Jun 2024; status: recruiting.
02
Drugs
tucidinostatdecitabine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06393361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393361.